Wilsons Research Report

Mar 3, 2022 | Company News

Recently WILSONS published its initiation research report on Hexima Limited (ASX:HXL) with an OVERWEIGHT rating and a $0.75 12-month price target. View the full report (pdf)

NailMail Q4 2021

Jan 31, 2022 | NailMail

Hexima is proud to release its “NailMail” quarterly activities report for the quarter ended 31 December 2021. Achievements for the quarter include:  Finishing the calendar year well capitalised with $14.3 million in cash at bank and R&D tax rebate receivable;...

Hexima featured at Edison Global Healthcare 2022

Jan 24, 2022 | Webinars & Events

Hexima was pleased to be featured at Edison Open House: Global Healthcare 2022. Edison Group is an investment research, investor relations and consulting firm with offices in North America, Europe, the Middle East and AsiaPac. It hosts Edison Open House: Global...

Phil Rose appointed Chief Commercial Officer

Jan 4, 2022 | Company News

Hexima announces the appointment of Phillip Rose as Chief Commercial Officer, based in the U.S. Phillip Rose reports to Michael Aldridge, Managing Director & CEO. Mr. Rose has over 30 years of leadership experience in the pharmaceutical industry, including...

Nancy Sacco appointed Chief Development Officer

Dec 2, 2021 | Company News

Hexima announces the appointment of Dr Nancy Sacco, PhD as Chief Development Officer. Dr Sacco will report to Michael Aldridge, Managing Director & CEO. Dr Sacco brings over 20 years of strong leadership experience in the pharmaceutical industry, driving business...